Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7616789 |
Synonyms | |
Therapy Description |
RO7616789 is a trispecific antibody that targets DLL3 on tumor cells and competitively binds to CD3 and TNFRSF9 (CD137), which results in increased CD3 and TNFRSF9 (CD137) signaling and activation of T-cells, potentially leading to decreased growth of DLL3-positive tumors (PMID: 38558120). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7616789 | RO 7616789|RO-7616789|RG6524|RG-6524|RG 6524|ALPS-12 | CD3 Antibody 99 | RO7616789 is a trispecific antibody that targets DLL3 on tumor cells and competitively binds to CD3 and TNFRSF9 (CD137), which results in increased CD3 and TNFRSF9 (CD137) signaling and activation of T-cells, potentially leading to decreased growth of DLL3-positive tumors (PMID: 38558120). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05619744 | Phase I | RO7616789 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | USA | POL | ESP | DNK | 1 |